Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 487-490, October 2005

Adjuvant UFT therapy does not increase survival in people with resected stage 1 non-small cell lung cancer☆☆☆☆☆☆

Meta-analysis Group, Medical Research Council Clinical Trials Unit, London, UK

published online 27 September 2005.

Abstracted from: Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M, Wada H. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)–the 4th study. Ann Oncol 2005;16:75–80.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Taiho pharmaceuticals Co., Ltd., Tokyo, Japan.

☆☆ For correspondence: Dr. H. Wada, Department of Thoracic Surgery,Kyoto University Hospital, Shogoin-kawara-cho 54, Sakyo-ku, Kyoto, 606-8507, Japan. Tel: +81 75 751 3835; fax: +81 75 751 4647. E-mail: wadah@kuhp.kyoto-u-ac.jp

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00133-7

doi:10.1016/j.ctrv.2005.07.002

Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 487-490, October 2005

Article Tools